Wednesday, March 11, 2015 (All day)

Burton on Trent, UK - 11 March 2015 - Clinigen Group plc ('Clinigen' or the 'Group', AIM: CLIN) today announces the extension and renegotiation of the exclusive license and distribution agreement with Hospira, Inc ('Hospira') for its anti-viral product Foscavir® (foscarnet sodium) in the US.  This is expected to be beneficial to both parties.

The original distribution agreement with Hospira established in July 2011 was due to expire in May 2017. The new agreement is for five years extending the term to 31 December 2019.

Foscavir® is Clinigen's lead product.  Foscavir® received FDA approval in May 2012 for the treatment ofHIV/AIDS-related cytomegalovirus infections and herpes. In September 2014, the FDA recognized the determined efforts made by Clinigen in providing Foscavir® to patients in the US by awarding Clinigen the first Drug Shortage Assistance Award.

Peter George, Chief Executive Officer, Clinigen Group said: "Hospira has been an excellent partner in the US, working closely with Clinigen since we acquired Foscavir®. The new five year agreement recognizes the strength of this partnership and shows the commitment of both Hospira and Clinigen to the continued supply of Foscavir® to US patients."

-Ends-

About Foscavir®

Foscavir® (foscarnet sodium) is an anti-viral licensed to treat cytomegalovirus (CMV) retinitis in HIV patients and for the treatment of acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections in immunocompromised patients.

About Clinigen Group

The Clinigen Group is a specialty global pharmaceutical company headquartered in the UK, with offices in the US and Japan. The Group, dedicated to delivering 'the right drug, to the right patient at the right time', has three operating businesses; Specialty Pharmaceuticals (Clinigen SP), Clinical Trials Supply (Clinigen CTS), and Global Access Programs (Clinigen GAP). Clinigen SP is focused on acquiring its own intellectual property in licensed, niche, hospital-only critical care medicines, increasing the value of these medicines by developing new formulations and indications, then registering and marketing them in defined global markets.

For more information, please visit www.clinigengroup.com.

Contact Details

Clinigen Group plc
Tel: +44 (0) 1283 495 010
Robin Sibson, Group Chief Financial Officer
Shaun Chilton, Group Chief Operating Officer

Instinctif Partners (media relations)
Tel: +44 (0) 20 7457 2020
Melanie Toyne Sewell/Jen Lewis/Emma Barlow
Email: clinigen@instinctif.com

Back to News